Intervention
Sacituzumab Tirumotecan
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 10 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
10 shownPhase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerNCT07329322 · 2026-03-30
RECRUITINGA Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)NCT07216703 · 2026-01-19
RECRUITINGSacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)NCT07179783 · 2025-09-22
RECRUITINGA Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)NCT06952504 · 2025-05-22
RECRUITINGSubstudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)NCT06445972 · 2024-08-07
RECRUITINGSacituzumab Tirumotecan in Pts w/ NEPC After Progression on Prior ChemotherapyNCT07639086 · 2026-08-31
NOT_YET_RECRUITINGGB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ)NCT07738341 · 2026-08-01
NOT_YET_RECRUITINGSacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLCNCT07388875 · 2026-02-24
NOT_YET_RECRUITINGSacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI TherapyNCT07193160 · 2025-11-01
NOT_YET_RECRUITINGSacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBCNCT07007780 · 2025-08-20
NOT_YET_RECRUITINGCommon conditions
Breast Cancer (Locally Advanced or Metastatic)1Cervical Cancer1Endometrial Cancer1Esophageal Cancer1Esophageal Neoplasms1Extensive-Stage Small Cell Lung Cancer1Gastroesophageal Adenocarcinoma1Gastroesophageal Junction1Neuroendocrine Prostate Cancer (NEPC)1Non-Small Cell Lung Cancer1NSCLC (Non-small Cell Lung Cancer)1Prostate Adenocarcinoma With Neuroendocrine Differentiation1Prostate Cancer1Prostate Cancer (Adenocarcinoma)1Prostate Cancer Metastatic Castration-Resistant1Triple -Negative Breast Cancer1
Leading sponsors
Trial status mix
NOT_YET_RECRUITING5
RECRUITING5
Phase mix
PHASE28
PHASE12
PHASE32
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.